Opus Genetics Free Cash Flow (FCF) History (IRD)

Opus Genetics reported −$6.8M in free cash flow for fiscal 2020, a decrease of $3.2M from the previous fiscal year.

View full Opus Genetics company overview

Opus Genetics free cash flow by year

Opus Genetics annual free cash flow

Fiscal yearPeriod endedFree cash flowChangeGrowthFCF margin
20202020-12-31−$6.8M−$3.2M
20192019-12-31−$3.6M$15.3M−120.60%
20182018-12-31−$18.9M−$3.4M
20172017-12-31−$15.5M−$2.3M
20162016-12-31−$13.2M$4.2M
20152015-12-31−$17.4M−$6.3M
20142014-12-31−$11.1M−$3.0M
20132013-12-31−$8.0M$7.5M
20112011-12-31−$15.5M−$8.6M
20102010-12-31−$7.0M−$1.8M
20092009-12-31−$5.2M

Opus Genetics free cash flow growth trends

Over the last five reported fiscal years, free cash flow grew from −$17.4M to −$6.8M, a net increase of $10.6M. Opus Genetics's latest reported quarter, Q4 2019, generated $5.0M in free cash flow, an increase of $9.6M year over year.

About the metric

What free cash flow means

Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.

Calculation and source

How free cash flow is calculated

TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.

Review Opus Genetics filings at SEC.gov ↗